PuREC

PuREC Co., Ltd.

基本情報

場所(HQ)

Shimane, JP

その他の場所

Tokyo, JP

からのスピンアウト

Shimane University Medical School

Webサイト

最高経営責任者(CEO

に設立されました 

Shotai Kobayashi

2016

事業内容

PuREC is currently preparing the IND for hypophosphatasia (a rare bone-formation deficiency disease for new born babies) with our uniquely purified MSC (mesenchymal stem cell). Two other orthopedic disease are expected to file IND in a few years. We are confident that our specially purified MSC, called “REC”, can be applied also for other disease areas as well.
As our first-in-human trial is expected to start in 2021, we seek for license partners and investors to solidify furhter development; esipecially in Europe and U.S.

ビジネス分野

Shimane University Medical School

キーワード

MSC

stem cell therapy

hypophosphatasia

disc herination

TRL

6

主要な文献

会社の価値観

出願された特許の数

4

特許ID

総特許額(USD)

No data

ビジネスステージ

Series A stage

要求されたコラボレーションの種類

R&D Collaboration, Investment, license partner

理想的な出口モデル

IPO in Japan

序章

PuREC is a spinout from Shimane University with patented technologies to produce purified MSC, or mesenchymal stem cells. PuREC's REC is coming from Rapidly Expanding Cells enabling the synthesis of 10^12 ordered pure cells within 12 weeks without requiring complicated methodologies such as gene-modification.

ライセンス供与の機会

(focusing on EU and US market)



Hypophosphatasia

Disc herniation

Joint disease

New applications including immunology diseases

投資機会

Target $10M by 2022



Target other disease target POC

Create global business development team



Global investors outside Japan are also welcome